Related references
Note: Only part of the references are listed.High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours
Grace Kong et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors
Philippe Brunner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation
U. Knigge et al.
NEUROENDOCRINOLOGY (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
Anders Sundin et al.
NEUROENDOCRINOLOGY (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification
Aurel Perren et al.
NEUROENDOCRINOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology Well Differentiated Versus Poorly Differentiated
Nitya Raj et al.
PANCREAS (2017)
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
Murali Kesavan et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2016)
Myeloid neoplasms after chemotherapy and PRRT: myth and reality
Lisa Bodei et al.
ENDOCRINE-RELATED CANCER (2016)
High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy
Bertrand Brieau et al.
ENDOCRINE-RELATED CANCER (2016)
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up
Dieter Hoersch et al.
EUROPEAN JOURNAL OF CANCER (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
[Lu-177-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide (Lu-177-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
Richard P. Baum et al.
THERANOSTICS (2016)
Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
Esther I. van Vliet et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)
Michael S. Hofman et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Consensus on biomarkers for neuroendocrine tumour disease
Kjell Oberg et al.
LANCET ONCOLOGY (2015)
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor
Armin Rashidi et al.
LEUKEMIA & LYMPHOMA (2015)
Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
Raghava Kashyap et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies
David A. Pattison et al.
PET CLINICS (2015)
[111In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy
Stefan E. Pool et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
Michael S. Hofman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study
Giovanni Paganelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
Samer Ezziddin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
G. Kong et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuro endocrine Tumors: A Long-Term Evaluation
Haifa Bahri et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion
Raghava Kashyap et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Maddalena Sansovini et al.
NEUROENDOCRINOLOGY (2013)
An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging
Price A. Jackson et al.
MEDICAL PHYSICS (2013)
Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
Phillip G. Claringbold et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable
T. W. Barber et al.
EJSO (2012)
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
Linda Villard et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms
Richard P. Baum et al.
SEMINARS IN NUCLEAR MEDICINE (2012)
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
Phillip G. Claringbold et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy
Giampiero Giovacchini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Jolanta Kunikowska et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Anna Imhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate
Saima Khan et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Peptide Receptor Radionuclide Therapy with Y-90-DOTATOC and Lu-177-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland
Andreas Klaus Pfeifer et al.
NEUROENDOCRINOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
R.J. Hicks
CANCER IMAGING (2011)
Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
Jean-Mathieu Beauregard et al.
CANCER IMAGING (2011)
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
J. B. Cwikla et al.
ANNALS OF ONCOLOGY (2010)
177Lu-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
Michael Garkavij et al.
CANCER (2010)
18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
Tina Binderup et al.
CLINICAL CANCER RESEARCH (2010)
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
Edgar J. Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
Daniel Hubble et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
David L. Bushnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90Y PET
Stephan Walrand et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
[Lu-177-DOTA(0)-Tyr(3)]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney
Christina Sward et al.
WORLD JOURNAL OF SURGERY (2010)
High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
Grace Kong et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT
Renaud Lhommel et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function
Jaap J. M. Teunissen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors
Etienne Garin et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate
Bart de Keizer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
Martijn van Essen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu- DOTA0, Tyr3] octreotide:: which peptide is preferable for PRRT?
J. P. Esser et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2006)
Large-volume liver metastases from neuroendocrine tumors:: Hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy
MKG McStay et al.
RADIOLOGY (2005)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Ty3-octreotide (SMT487 [OctreoTher™]) treatment
D Bushnell et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
A Helisch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) -: a phase 1 clinical study:: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion
F Jamar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study
L Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
LB Anthony et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide:: The experience of the European Institute of Oncology Group
M Chinol et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Y-90-DOTA-D-Phe(1)-Try(3)-octreotide in therapy of neuroendocrine malignancies
G Paganelli et al.
BIOPOLYMERS (2002)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study
C Waldherr et al.
ANNALS OF ONCOLOGY (2001)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
Share Paper
